Teva Pharmaceutical Industries (NYSE:TEVA) Q4 results:
Revenues:$4,468M (+1%); North America: $2,373M (+6%); Generics: $2,497M (+2%), Copaxone: $387M (-22%).
Net income: $110M (+104%); non-GAAP net income: $683M (+26%); EPS: ($0.91); non-GAAP EPS: $0.10 (+104%).
Consensus was non-GAAP EPS of $0.61 on revenues of $4.35B.
Cash flow ops (full year): $748M (-69%). Decrease mainly due to the working capital adjustment with Allergan and the Rimsa settlement in 2018 and lower profits in North America in 2019.
Cash flow ops in Q4: $538M (+47%).
All components of 2019 outlook met, including spend base reduction target of $3B.
2020 guidance: Revenues: $16.6B - 17.0B; Copaxone sales: ~$1.2B; Austedo sales: ~$650M; AJOVY sales: ~$250M; non-GAAP EPS: $2.30 - 2.55; free cash flow: $1.8B - 2.2B.
Source Seeking ALPHA
Revenues:$4,468M (+1%); North America: $2,373M (+6%); Generics: $2,497M (+2%), Copaxone: $387M (-22%).
Net income: $110M (+104%); non-GAAP net income: $683M (+26%); EPS: ($0.91); non-GAAP EPS: $0.10 (+104%).
Consensus was non-GAAP EPS of $0.61 on revenues of $4.35B.
Cash flow ops (full year): $748M (-69%). Decrease mainly due to the working capital adjustment with Allergan and the Rimsa settlement in 2018 and lower profits in North America in 2019.
Cash flow ops in Q4: $538M (+47%).
All components of 2019 outlook met, including spend base reduction target of $3B.
2020 guidance: Revenues: $16.6B - 17.0B; Copaxone sales: ~$1.2B; Austedo sales: ~$650M; AJOVY sales: ~$250M; non-GAAP EPS: $2.30 - 2.55; free cash flow: $1.8B - 2.2B.
Source Seeking ALPHA
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.